Open AccessLiposomes: A Novel Carrier for Targeted Delivery of Active Agents against Schizophrenia
Author(s) -
Radha Arulkumar,
P Muthumari,
S Mounisha,
C Indrapriyadharshini,
Ardra Krishna
Publication year - 2021
Publication title -
international journal of pharmaceutical sciences review and research
Language(s) - English
Resource type - Journals
ISSN - 0976-044X
DOI - 10.47583/ijpsrr.2021.v69i02.008
Subject(s) - schizophrenia (object oriented programming) , clozapine , psychiatry , psychology , psychotherapist , medicine
Schizophrenia is a severe brain disorder in which people have abnormal perceptions of reality. Schizophrenia can cause hallucinations, delusions, and extremely disordered thinking and behavior. Schizophrenia, contrary to popular belief, is not a split or multiple personality disorder. The term "schizophrenia" literally means "split mind," but it refers to a disruption in the normal balance of thoughts. Clozapine is currently the only medication approved by the USFDA for the treatment of refractory schizophrenia. However, for patients who do not respond to clozapine or for whom clozapine therapy fails to treat refractory schizophrenia, a combination of antipsychotics is used. Overall, the focus of this article is to summaries the most recent findings and news concerning liposome technology in the treatment of neurodegenerative diseases, as well as to demonstrate the potential of this technology for the development of novel therapeutics and the potential applications of liposomes in the two most common Schizophrenia disorders.